Shots:
- Takeda has reported the 2 P-III (Latitude PsO 3001 & PsO 3002) trial results assessing zasocitinib (QD, PO) in 693 & 1108 adults, respectively, with mod. to sev. PsO, where both studies showed improved NAPSI scores vs PBO at 16wks.
- Trials also showed that 77% (3001) & 74% (3002) pts reached ssPGA 0/1 response vs PBO (7% & 13%) & apremilast (42% & 30%) at 16wks.; 71% & 69% palmoplantar PsO pts achieved hfPGA 0/1 vs PBO (22% & 10%) & apremilast (44% & 43%)
- Also, Takeda plans to submit an NDA for plaque PsO to the FDA & other regulators this fiscal year, while zasocitinib is also being evaluated in P-III studies for PsA & P-II studies for Crohn’s disease, ulcerative colitis, vitiligo, & hidradenitis suppurativa
Ref: Businesswire | Image: Takeda | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
